{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T21:10:26Z","timestamp":1786655426233,"version":"build-2736575974"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T00:00:00Z","timestamp":1725840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","msard-journal.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.msard.2024.105880","type":"journal-article","created":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T22:21:15Z","timestamp":1725661275000},"page":"105880","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Alemtuzumab-induced thyroid disease: A Danish cohort study"],"prefix":"10.1016","volume":"91","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-8436-801X","authenticated-orcid":false,"given":"Juliana Frohnert","family":"Hansen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda","family":"Magyari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5se Krogh","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Finn","family":"Sellebjerg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Feldt-Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.msard.2024.105880_bib0001","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.beem.2014.01.001","article-title":"Epidemiology of nodular goitre. Influence of iodine intake","volume":"28","author":"Carl\u00e9","year":"2014","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"issue":"11","key":"10.1016\/j.msard.2024.105880_bib0002","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology."},{"issue":"17","key":"10.1016\/j.msard.2024.105880_bib0003","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1056\/NEJMoa0802670","article-title":"Alemtuzumab vs. interferon beta-1a in early multiple sclerosis","volume":"359","author":"Coles","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"9191","key":"10.1016\/j.msard.2024.105880_bib0004","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(99)02429-0","article-title":"Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis","volume":"354","author":"Coles","year":"1999","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.msard.2024.105880_bib0005","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1210\/jc.2013-2201","article-title":"Alemtuzumab-related thyroid dysfunction in a phase 2 trial of patients with relapsing-remitting multiple sclerosis","volume":"99","author":"Daniels","year":"2014","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"9","key":"10.1016\/j.msard.2024.105880_bib0006","doi-asserted-by":"crossref","first-page":"3624","DOI":"10.1210\/jc.2018-02435","article-title":"Letter to the editor: \"alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features\"","volume":"104","author":"Garrahy","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6","key":"10.1016\/j.msard.2024.105880_bib0007","doi-asserted-by":"crossref","DOI":"10.1210\/jendso\/bvab044","article-title":"Management of severe graves' hyperthyroidism in pregnancy following immune reconstitution therapy in multiple sclerosis","volume":"5","author":"Hammerstad","year":"2021","journal-title":"J. Endocr. Soc."},{"issue":"11","key":"10.1016\/j.msard.2024.105880_bib0008","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.0000000000004313","article-title":"Alemtuzumab CARE-MS I 5-year follow-up: durable efficacy in the absence of continuous MS therapy","volume":"89","author":"Havrdova","year":"2017","journal-title":"Neurology."},{"issue":"3","key":"10.1016\/j.msard.2024.105880_bib0009","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/jnnp-2011-300826","article-title":"Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis","volume":"83","author":"Hill-Cawthorne","year":"2012","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2024.105880_bib0010","author":"Manso","year":"2021","journal-title":"Alemtuzumab-Induced Autoimmune Thyroid Events in Patients With Relapsing-Remitting Multiple Sclerosis: A real-Life and Monocentric Experience At a Tertiary-Level Centre"},{"issue":"8918","key":"10.1016\/j.msard.2024.105880_bib0011","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(94)91339-0","article-title":"Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis","volume":"344","author":"Moreau","year":"1994","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.msard.2024.105880_bib0012","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1159\/000500881","article-title":"2019 European thyroid association guidelines on the management of thyroid dysfunction following immune reconstitution therapy","volume":"8","author":"Muller","year":"2019","journal-title":"Eur. Thyroid. J."},{"issue":"12","key":"10.1016\/j.msard.2024.105880_bib0013","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1089\/thy.2018.0232","article-title":"Longitudinal characterization of autoantibodies to the thyrotropin receptor (TRAb) during alemtuzumab therapy: evidence that TRAb may precede thyroid dysfunction by many years","volume":"28","author":"Muller","year":"2018","journal-title":"Thyroid"},{"key":"10.1016\/j.msard.2024.105880_bib0014","doi-asserted-by":"crossref","first-page":"31969","DOI":"10.3402\/fnr.v60.31969","article-title":"Iodine status in the Nordic countries - past and present","volume":"60","author":"Nystr\u00f6m","year":"2016","journal-title":"Food Nutr. Res."},{"issue":"8","key":"10.1016\/j.msard.2024.105880_bib0015","doi-asserted-by":"crossref","first-page":"3010","DOI":"10.1210\/jc.2018-00359","article-title":"Alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features","volume":"103","author":"Pariani","year":"2018","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"6162","key":"10.1016\/j.msard.2024.105880_bib0016","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/332323a0","article-title":"Reshaping human antibodies for therapy","volume":"332","author":"Riechmann","year":"1988","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.msard.2024.105880_bib0017","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/brain\/awac064","article-title":"Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity","volume":"145","author":"Ruck","year":"2022","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.msard.2024.105880_bib0018","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40618-019-01105-7","article-title":"Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis","volume":"43","author":"Scappaticcio","year":"2020","journal-title":"J. Endocrinol. Invest."},{"issue":"9","key":"10.1016\/j.msard.2024.105880_bib0019","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1210\/jc.2018-02593","article-title":"Response to letter to the editor: \"alemtuzumab-induced thyroid dysfunction exhibits distinctive clinical and immunological features\"","volume":"104","author":"Thakar","year":"2019","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.msard.2024.105880_bib0020","author":"Ueland","year":"2023","journal-title":"Prevalence, Risk factors, Clinical and Biochemical Characteristics of Alemtuzumab-induced Graves' Disease"},{"issue":"6","key":"10.1016\/j.msard.2024.105880_bib0021","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.beem.2009.07.003","article-title":"Immune reconstitution syndrome and the thyroid","volume":"23","author":"Weetman","year":"2009","journal-title":"Best. Pract. Res. Clin. Endocrinol. Metab."},{"issue":"2","key":"10.1016\/j.msard.2024.105880_bib0022","article-title":"Alemtuzumab-related thyroid disease in people with multiple sclerosis is associated with age and brainstem phenotype at disease onset","volume":"6","author":"Yap","year":"2020","journal-title":"Mult. Scler. J. Exp. Transl. Clin."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824004565?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034824004565?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,23]],"date-time":"2024-11-23T04:30:22Z","timestamp":1732336222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034824004565"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":22,"alternative-id":["S2211034824004565"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.105880","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alemtuzumab-induced thyroid disease: A Danish cohort study","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.105880","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105880"}}